Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,069 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (Cohort 3) Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 14, 2026, 10:31 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

LH-001 vs Placebo in Healthy Participants

NCT06546449
View directory record Official record
Conditions
Healthy
Interventions
LH-001, Placebo
Drug
Lead sponsor
Chien-Liang Lin
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

NCT02623699
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tofersen, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 14, 2026, 10:31 AM EDT
Withdrawn Not applicable Interventional

Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

NCT03228121
View directory record Official record
Conditions
COPD, Emphysema or COPD, Chronic Bronchitis
Interventions
Treatment Then Placebo, Placebo Then Treatment
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

NCT03919409
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-161, TS-161 Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

NCT04493684
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3739937 (PIB), Placebo, GSK3739937 (Tablet)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 14, 2026, 10:31 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Auxora in Patients With Critical COVID-19 Pneumonia

NCT04661540
View directory record Official record
Conditions
Pneumonia
Interventions
CM4620-IE (Injectable Emulsion), Placebo
Drug
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 10:31 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

NCT04593784
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device)
Drug · Device
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3009104(Baricitinib) for Healthy Subjects

NCT01247350
View directory record Official record
Conditions
Healthy Volunteer
Interventions
LY3009104, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 14, 2026, 10:31 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4178256 in Healthy Participants

NCT07698210
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY4178256, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Alamitos, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04537208
View directory record Official record
Conditions
COVID-19 (Healthy Volunteers)
Interventions
CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults

NCT03046550
View directory record Official record
Conditions
Healthy
Interventions
NTM-1634, Placebo
Drug
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 48 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects

NCT00856310
View directory record Official record
Conditions
Healthy
Interventions
REGN475 (SAR164877)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Altoona, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

NCT01831804
View directory record Official record
Conditions
Wound Healing
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
7
States / cities
Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers

NCT04984525
View directory record Official record
Conditions
Healthy
Interventions
SYNB1934, SYNB1618
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-071 in People With Parkinson Disease

NCT04334317
View directory record Official record
Conditions
Parkinson Disease, Healthy Participants
Interventions
TAK-071, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Garden Grove, California • Irvine, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1Phase 2 Interventional

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

NCT02718495
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PTI-428, Placebo
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Stanford, California • Altamonte Springs, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 14, 2026, 10:31 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study

NCT01376765
View directory record Official record
Conditions
SARS
Interventions
Aluminum hydroxide adjuvant (Alhydrogel®), Phosphate buffered saline Placebo, Recombinant S protein SARS vaccine
Drug · Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
3
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of an Extract of Naringenin

NCT03582553
View directory record Official record
Conditions
Safety Issues, Pharmacokinetics
Interventions
Naringenin, Placebo
Dietary Supplement · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

NCT02207790
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

LMN-101 in a Campylobacter Human Challenge Model

NCT04182490
View directory record Official record
Conditions
Campylobacter Infections
Interventions
LMN-101, Placebo
Biological · Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

NCT03817424
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis
Interventions
VIB7734, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 14, 2026, 10:31 AM EDT
Terminated Phase 1 Interventional

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

NCT01470313
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
PD-0360324, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Anniston, Alabama • Oxford, Alabama • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 14, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

NCT04505397
View directory record Official record
Conditions
Healthy
Interventions
SKL24741, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 14, 2026, 10:31 AM EDT